$NKTR News Article - Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma https://marketwirenews.com/news-releases/nekt...08961.html